• Corpus ID: 25335283

Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules.

@article{Aherne2001PharmacokineticpharmacodynamicSO,
  title={Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules.},
  author={G. Wynne Aherne and Anthea Hardcastle and Erica N. Ward and Donna Dobinson and Thomas Roy Crompton and Melanie Valenti and Lisa Brunton and Ann L. Jackman},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2001},
  volume={7 9},
  pages={
          2923-30
        }
}
  • G. Aherne, A. Hardcastle, A. Jackman
  • Published 1 September 2001
  • Biology, Medicine, Chemistry
  • Clinical cancer research : an official journal of the American Association for Cancer Research
ZD9331 is a nonpolyglutamatable antifolate inhibitor of thymidylate synthase currently in clinical development. This enzyme is crucial for DNA synthesis and catalyzes the reductive methylation of dUMP to form thymidylate, which is subsequently converted to dTTP. The pharmacokinetics of two curative antitumor doses of ZD9331 administered by either a single i.p. bolus injection (50 mg/kg) or by 24-h s.c. infusion (3 mg/kg) have been measured in a thymidine salvage-incompetent murine lymphoma… 

Figures and Tables from this paper

A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies
TLDR
The combination regimen, consisting of ZD9331 and docetaxel, is feasible and well tolerated at single-agent doses that are clinically-relevant and does not appear to be associated with either major pharmacokinetic or toxicologic drug-drug interactions.
ZD9331: discovery to clinical development
TLDR
ZD9331 is a rationally designed third-generation specific inhibitor of TS that does not require polyglutamation for its activity and is likely to be transported by the ubiquitously expressed reduced folate carrier as well as the a-folate receptor which is overexpressed in some cancers, especially ovarian.
A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies
TLDR
The combination of BGC9331 and carboplatin is well tolerated with no significant PK interaction between the two drugs and evidence of TS inhibition with the combination is demonstrated.
New targets for an old drug
TLDR
Light is shed into the mechanism of action of methotrexate in oncology and other highly proliferative diseases and may help explain some unaccounted for effects of this drug.
The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels
TLDR
This study shows that in vivo [18F]FLT kinetics depend on TK1 protein expression and has the potential to yield specific information on tumour proliferation in diagnostic imaging and therapy monitoring.
New targets for an old drug
TLDR
A chemical proteomics approach that uses ultra-sensitive mass spectrometry coupled to an inverse protein-ligand docking computational technique to unravel the mechanism of action of methotrexate and effectively captured a large portion of the de novo purine metaolome, demonstrating that this proteomics technology could play an important role in drug discovery and development.
Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts.
TLDR
A rapid screen to monitor PD responses within xenografted human tumors as an important step towards a clinically applicable technology is developed and optimized of the Meso Scale Discovery (MSD) platform.
Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.
TLDR
Novel solid-phase immunoassays have been validated using a time-resolved fluorescence (TRF) end point and their utility for confirming the mechanism of action of Hsp90 inhibition in secondary cell-based assays has been shown and applied to the novel HSP90 inhibitor CCT018159.

References

SHOWING 1-10 OF 34 REFERENCES
The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice.
TLDR
Data show that ZD9331 is non-nephrotoxic at active anti-tumour doses (50 mg kg(-1) i.p.) in mice, and only at very high bolus i.v. doses is there impaired renal function as a result of very high peak plasma concentrations, indicating the likely need for short infusions in clinical settings.
Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.
TLDR
Although it has not been possible to measure individual polyglutamated forms of ZD1694, the radioimmunoassay provides a convenient means of assessing total drug levels in tissues and is currently the only method suitable for measuring the extent of drug retention in normal tissue and tumour biopsies obtained from patients treated with ZD 1694.
Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.
CB30900 is a novel, potent thymidylate synthase inhibitor which can not be polyglutamated and may be active in cancers expressing low or defective folylpolyglutamate synthetase. Pharmacokinetics were
Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
  • A. Jackman, R. Kimbell, F. T. Boyle
  • Biology, Chemistry
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
TLDR
ZD9331 had antitumor activity against the L5178Y TK+/- tumor when administered by 7-day continuous infusion; growth delays of more than 5 days (and some cures) were seen at doses of 25-50 mg/kg/day.
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
TLDR
The L1210:1565 cell line, which has greatly impaired reduced-folate/methotrexate transport and thus is resistant to methotrexate, was significantly cross-resistant to ICI D1694, suggesting that ICID1694 is dependent on this uptake mechanism for good cytotoxic potency in L 1210 cells.
The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in mice.
A sensitive and specific radioimmunoassay for LY309887, a potent inhibitor of glycinamide ribonucleotide formyltransferase.
TLDR
The sensitivity of the RIA permitted the demonstration that serum concentrations of LY309887 decline in a multiexponential manner with a prolonged terminal elimination phase, and it is concluded that the Ria is a valid method for quantifying Ly309887 in biological fluids.
Section Review: Oncologic, Endocrine & Metabolic: The new generation of thymidylate synthase inhibitors in clinical study
TLDR
Six new antifolate drugs, all targeted towards thymidylate synthase (TS), have entered clinical studies and early indications suggest that some of these may have promising activity in a number of tumour types.
...
1
2
3
4
...